Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers
Gustavo Arango-Argoty(AstraZeneca (South Korea)), Etai Jacob(AstraZeneca (United States)), Gerald J. Sun(AstraZeneca (United States)), Ross Stewart(AstraZeneca (United Kingdom)), Arijit Patra(UCB Pharma (United States)), Elly Kipkogei(AstraZeneca (United States)), Ioannis Kagiampakis(Johns Hopkins University)
Cited by 28
Related Papers
DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data
|Microbiome|2018|962
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|The Lancet Oncology|2021|401
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
|Cancer Cell|2024|177
An in-depth map of polyadenylation sites in cancer
|Nucleic Acids Research|2012|151